Site Search
Professionals 74 results
Capabilities 25 results
Practice Area
Securities, M&A & Corporate Governance Litigation
In today’s market, litigators with experience in securities, corporate governance, and M&A-related (collectively, “securities litigation”) matters need to leverage their broad experience to serve as both advocate and as counsel and strategist, focused on helping clients to overcome not just a legal issue but a collective business problem. Given the frequent interplay between things such as corporate-control transactions, public offerings, activist shareholders, the use of complex derivatives and other financial instruments, bad news impacting stock performance, regulatory inquiries and investigations, and insurance coverage, strategic and tactical litigation decisions can have a wide-ranging impact on the success of a given transaction, as well as on companies, their boards, senior management, and advisors.
Practice Area
Our structured finance group is widely recognized as a leader, encompassing Esoteric Finance, Residential Asset Finance and Securitization, and CLOs/Fund Finance. Positioned prominently at the forefront of the industry, our team boasts extensive experience across a broad spectrum of assets, with a particular focus on bespoke structures and emerging and/or “esoteric” assets, including residential and commercial PACE, RMBS, and CMBS; aircraft, vessel, and railcar finance; FinTech and marketplace lending; CLOs; specialty finance; consumer and business lending; energy structured finance (including solar finance and reserve-based finance); derivatives and structured products; lease and operating asset finance; trade receivables; litigation settlement financing; and life settlements.
Practice Area
As society and business become even more digitalized, technology and intellectual property (IP) have become key focal points for businesses. Our Technology Antitrust Group combines the cross-practice and cross-office experience of our lawyers to assist clients in successfully navigating the dynamic convergence of technology, antitrust, and IP law. We understand the challenges presented by the ever-changing digital landscape and are committed to providing our clients with tailored solutions to address their specific needs.
Experience 4 results
Experience
|June 14, 2024
Winston Represented Charles Thayne Capital in its Acquisition of Bluescape
Experience
|July 8, 2021
Alpha Tau Medical Ltd. and Healthcare Capital Corp. Announce Business Combination
Winston & Strawn LLP represented the placement agents in connection with the business combination between Alpha Tau Medical Ltd. (Alpha Tau), the developer of the pioneering alpha-radiation cancer therapy Alpha DaRT™, and Healthcare Capital Corp. (HCC) (Nasdaq: HCCC), a special purpose acquisition company. The business combination values Alpha Tau at an implied pre-money equity value of US$600M, and is expected to add approximately US$337M of cash to its balance sheet upon closing, inclusive of US$275M in HCC's trust (assuming no redemptions by public shareholders) and US$92M in PIPE proceeds, net of transaction expenses. All existing Alpha Tau shareholders will retain 100% of their current equity holdings and are expected to hold approximately 59% of the pro forma company immediately following the closing. Following the closing of the business combination, Alpha Tau is expected to be listed on the Nasdaq. The completion of this transaction will allow the company to realize its vision and implement the clinical development plans and construction of manufacturing plants around the world and ensures they are well capitalized to accelerate ambitious plans across multiple fronts. Proceeds of the business combination and the PIPE will be primarily used to: advance ongoing, and launch new, clinical trials; continue existing, and initiate additional, clinical and research collaborations; develop and expand global manufacturing capacity; develop KOL centers of excellence; and prepare for commercialization efforts.
Insights & News 319 results
Client Alert
|May 1, 2025
|3 Min Read
April 2025 Executive Order Targets Prescription Drug Price Reduction
On April 15, 2025, President Trump signed an executive order titled “Lowering Drug Prices by Once Again Putting Americans First.” The subject matter of this executive order criss-crosses considerable policy ground in the overall U.S. pharmaceutical distribution chain. The executive order sets forth the administration’s statement of objectives to reduce prescription medication costs by promoting competition and eliminating practices that lead to high drug prices. Referencing regulatory and policy actions from the first Trump administration and the Biden administration’s policy steps, including the Inflation Reduction Act of 2022 aimed at lowering prescription drug prices for Medicare beneficiaries, the executive order sets forth a broad agenda to impact Medicare prescription drug costs, including in the Medicare Part D program.[1] The order directs the Secretary of Health and Human Services (HHS) to propose and seek comment on guidance for the Medicare Drug Price Negotiation Program and collaborate with Congress to align the treatment of small molecule drugs with biological products, citing concerns about industry investment distortions and cost increases for Medicare and its beneficiaries.[2]
Press Release
|April 22, 2025
|1 Min Read
Winston & Strawn Appoints Amy Kotulski as Chief Operating Officer
New York – April 22, 2025 – Winston & Strawn LLP is pleased to announce the appointment of Amy Kotulski as Chief Operating Officer (COO).
In the Media
|April 7, 2025
|2 Min Read
Stan Kalminsky Joins Winston & Strawn in Los Angeles
Winston & Strawn recently announced the addition of Stanislav (“Stan”) Kalminsky as a partner in the firm’s Los Angeles office. He joins the Transactions Department. Stan has represented public and private companies, as well as private equity funds and their portfolio companies, in a variety of transactions, including mergers, stock and asset acquisitions and dispositions, cross-border transactions, joint ventures, leveraged buyouts, and restructurings.
Other Results 17 results
Site Content
Location
Serving one of the world’s largest economies for over 20 years, Winston & Strawn’s Los Angeles office is home to more than 100 lawyers and business professionals. Under the guidance of Office Managing Partner Angela Machala, our L.A. office thrives as a dynamic and tightly knit community with an inclusive culture in which its members from all backgrounds, experiences, and perspectives collaborate closely to support each other’s success and achieve their clients’ goals. Our L.A. lawyers—who are equally split between litigation and transactional work—advise 80+ Fortune 500 companies, which is a testament to the collaborative environment we’ve created to provide exceptional legal services.
Location
Opened in 2017, Winston & Strawn’s Dallas office is located in the cultural and economic epicenter of DFW, the fourth largest metropolitan area in the U.S. and the fastest growing over the last year. Our Dallas attorneys litigate both high-stakes civil and criminal matters, including major state and federal trials and appeals nationwide, and represent clients in complex transactional matters. Under the leadership of Bryan L. Goolsby, our office—made up of nearly 100 lawyers—continues to expand, attracting some of the country’s top legal talent to meet the increased needs of the many technology, investment, and health care companies that are increasingly making Dallas their home.